{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T16:13:49Z","timestamp":1786119229662,"version":"build-2736575974"},"reference-count":42,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"9","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2013,10]]},"DOI":"10.1097\/cad.0b013e3283645e1a","type":"journal-article","created":{"date-parts":[[2013,8,9]],"date-time":"2013-08-09T07:24:12Z","timestamp":1376033052000},"page":"958-968","source":"Crossref","is-referenced-by-count":8,"title":["Coadministration of lapatinib increases exposure to docetaxel but not doxorubicin in the small intestine of mice"],"prefix":"10.1097","volume":"24","author":[{"given":"Susan F.","family":"Hudachek","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel L.","family":"Gustafson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R3-10-20210203","doi-asserted-by":"crossref","first-page":"673","DOI":"10.6004\/jnccn.2007.0069","article-title":"Counterpoint: the argument for combination chemotherapy in the treatment of metastatic breast cancer.","volume":"5","author":"Cianfrocca","year":"2007","journal-title":"J Natl Compr Canc Netw"},{"key":"R4-10-20210203","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/0005-2736(76)90160-7","article-title":"A surface glycoprotein modulating drug permeability in Chinese hamster ovary cell mutants.","volume":"455","author":"Juliano","year":"1976","journal-title":"Biochim Biophys Acta"},{"key":"R5-10-20210203","doi-asserted-by":"crossref","first-page":"7735","DOI":"10.1073\/pnas.84.21.7735","article-title":"Cellular localization of the multidrug-resistance gene product p-glycoprotein in normal human tissues.","volume":"84","author":"Thiebaut","year":"1987","journal-title":"Proc Natl Acad Sci USA"},{"key":"R6-10-20210203","doi-asserted-by":"crossref","first-page":"1346","DOI":"10.1128\/MCB.9.3.1346","article-title":"The three mouse multidrug resistance (mdr) genes are expressed in a tissue-specific manner in normal mouse tissues.","volume":"9","author":"Croop","year":"1989","journal-title":"Mol Cell Biol"},{"key":"R8-10-20210203","doi-asserted-by":"crossref","first-page":"1699","DOI":"10.1095\/biolreprod.102.003558","article-title":"Multidrug resistance genes and p-glycoprotein in the testis of the rat, mouse, guinea pig, and human.","volume":"67","author":"Melaine","year":"2002","journal-title":"Biol Reprod"},{"key":"R9-10-20210203","doi-asserted-by":"crossref","first-page":"1626","DOI":"10.1128\/AAC.49.4.1626-1628.2005","article-title":"Role of p-glycoprotein in distribution of nelfinavir across the blood-mammary tissue barrier and blood-brain barrier.","volume":"49","author":"Edwards","year":"2005","journal-title":"Antimicrob Agents Chemother"},{"key":"R10-10-20210203","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1038\/sj.bjc.6690019","article-title":"Increased accumulation of doxorubicin and doxorubicinol in cardiac tissue of mice lacking mdr1a p-glycoprotein.","volume":"79","author":"Van Asperen","year":"1999","journal-title":"Br J Cancer"},{"key":"R11-10-20210203","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.canlet.2004.09.007","article-title":"Pharmacokinetics of combined doxorubicin and paclitaxel in mice.","volume":"220","author":"Gustafson","year":"2005","journal-title":"Cancer Lett"},{"key":"R12-10-20210203","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1007\/s10637-009-9266-0","article-title":".Tyrosine kinase inhibitors potentiate the cytotoxicity of mdr-substrate anticancer agents independent of growth factor receptor status in lung cancer cell lines.","volume":"28","author":"Collins","year":"2010","journal-title":"Invest New Drugs"},{"key":"R13-10-20210203","doi-asserted-by":"crossref","first-page":"7905","DOI":"10.1158\/0008-5472.CAN-08-0499","article-title":".Lapatinib (Tykerb, GW572016) reverses multidrug resistance in cancer cells by inhibiting the activity of ATP-binding cassette subfamily B member 1 and G member 2.","volume":"68","author":"Dai","year":"2008","journal-title":"Cancer Res"},{"key":"R14-10-20210203","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/j.jchromb.2005.11.044","article-title":"3rd, Fraga CH, Fouladi M, Stewart CF.Determination of lapatinib (GW572016) in human plasma by liquid chromatography electrospray tandem mass spectrometry (LC-ESI-MSMS).","volume":"831","author":"Bai","year":"2006","journal-title":"J Chromatogr B Analyt Technol Biomed Life Sci"},{"key":"R15-10-20210203","doi-asserted-by":"crossref","first-page":"3753","DOI":"10.1200\/JCO.2007.11.1765","article-title":".Phase I and pharmacokinetic study of lapatinib in combination with capecitabine in patients with advanced solid malignancies.","volume":"25","author":"Chu","year":"2007","journal-title":"J Clin Oncol"},{"key":"R16-10-20210203","doi-asserted-by":"crossref","first-page":"2768","DOI":"10.1158\/1078-0432.CCR-06-2362","article-title":"A physiologically based pharmacokinetic model of docetaxel disposition: from mouse to man.","volume":"13","author":"Bradshaw-Pierce","year":"2007","journal-title":"Clin Cancer Res"},{"key":"R17-10-20210203","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1007\/s00280-003-0622-z","article-title":"Analysis of docetaxel pharmacokinetics in humans with the inclusion of later sampling time-points afforded by the use of a sensitive tandem LCMS assay.","volume":"52","author":"Gustafson","year":"2003","journal-title":"Cancer Chemother Pharmacol"},{"key":"R18-10-20210203","doi-asserted-by":"crossref","first-page":"1488","DOI":"10.1002\/jps.10161","article-title":"Doxorubicin pharmacokinetics: macromolecule binding, metabolism, and excretion in the context of a physiologic model.","volume":"91","author":"Gustafson","year":"2002","journal-title":"J Pharm Sci"},{"key":"R19-10-20210203","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/0378-4347(91)80218-2","article-title":"Simple and sensitive quantification of anthracyclines in mouse atrial tissue using high-performance liquid chromatography and fluorescence detection.","volume":"570","author":"De Jong","year":"1991","journal-title":"J Chromatogr"},{"key":"R20-10-20210203","doi-asserted-by":"crossref","first-page":"4484","DOI":"10.1158\/1078-0432.CCR-07-4417","article-title":".A phase I and pharmacokinetic study of lapatinib in combination with letrozole in patients with advanced cancer.","volume":"14","author":"Chu","year":"2008","journal-title":"Clin Cancer Res"},{"key":"R21-10-20210203","doi-asserted-by":"crossref","first-page":"7900","DOI":"10.1158\/1078-0432.CCR-08-0415","article-title":".Evaluation of lapatinib and topotecan combination therapy: tissue culture, murine xenograft, and phase I clinical trial data.","volume":"14","author":"Molina","year":"2008","journal-title":"Clin Cancer Res"},{"key":"R22-10-20210203","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.ygyno.2008.07.001","article-title":".A phase I study of lapatinib in combination with carboplatin in women with platinum sensitive recurrent ovarian carcinoma.","volume":"111","author":"Kimball","year":"2008","journal-title":"Gynecol Oncol"},{"key":"R23-10-20210203","doi-asserted-by":"crossref","first-page":"3051","DOI":"10.1200\/JCO.2007.14.9633","article-title":".Phase I and pharmacokinetic study of lapatinib and docetaxel in patients with advanced cancer.","volume":"26","author":"LoRusso","year":"2008","journal-title":"J Clin Oncol"},{"key":"R24-10-20210203","doi-asserted-by":"crossref","first-page":"3317","DOI":"10.1200\/JCO.2007.13.5202","article-title":".Phase I dose escalation and pharmacokinetic study of lapatinib in combination with trastuzumab in patients with advanced ERBB2-positive breast cancer.","volume":"26","author":"Storniolo","year":"2008","journal-title":"J Clin Oncol"},{"key":"R25-10-20210203","doi-asserted-by":"crossref","first-page":"2025","DOI":"10.1093\/annonc\/mdm366","article-title":".A phase I and pharmacokinetic study of lapatinib in combination with infusional 5-fluorouracil, leucovorin and irinotecan.","volume":"18","author":"Midgley","year":"2007","journal-title":"Ann Oncol"},{"key":"R26-10-20210203","doi-asserted-by":"crossref","first-page":"4495","DOI":"10.1158\/1078-0432.CCR-07-0004","article-title":".Phase I pharmacokinetic study of the safety and tolerability of lapatinib (GW572016) in combination with oxaliplatinfluorouracilleucovorin (FOLFOX4) in patients with solid tumors.","volume":"13","author":"Siegel-Lakhai","year":"2007","journal-title":"Clin Cancer Res"},{"key":"R27-10-20210203","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1124\/dmd.111.040949","article-title":"Human metabolism of lapatinib, a dual kinase inhibitor: implications for hepatotoxicity.","volume":"40","author":"Castellino","year":"2012","journal-title":"Drug Metab Dispos"},{"key":"R28-10-20210203","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1124\/dmd.107.018374","article-title":".The role of efflux and uptake transporters in n-3-chloro-4-(3-fluorobenzyl)oxyphenyl-6-5-(2-(methylsulfonyl)ethylaminomethyl)-2-furyl-4-quinazolinamine (GW572016, lapatinib) disposition and drug interactions.","volume":"36","author":"Polli","year":"2008","journal-title":"Drug Metab Dispos"},{"key":"R29-10-20210203","doi-asserted-by":"crossref","first-page":"e25815","DOI":"10.1371\/journal.pone.0025815","article-title":".Predicting p-glycoprotein-mediated drug transport based on support vector machine and three-dimensional crystal structure of p-glycoprotein.","volume":"6","author":"Bikadi","year":"2011","journal-title":"PLoS One"},{"key":"R33-10-20210203","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1097\/00001813-199512000-00004","article-title":"Cardiotoxicity in the scid mouse following administration of doxorubicin and cyclosporin a.","volume":"6","author":"Bellamy","year":"1995","journal-title":"Anticancer Drugs"},{"key":"R34-10-20210203","first-page":"22","article-title":"Cyclosporin a markedly changes the distribution of doxorubicin in mice and rats.","volume":"269","author":"Colombo","year":"1994","journal-title":"J Pharmacol Exp Ther"},{"key":"R35-10-20210203","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1007\/BF00689051","article-title":"Changes in doxorubicin distribution and toxicity in mice pretreated with the cyclosporin analogue SDZ PSC 833.","volume":"36","author":"Gonzalez","year":"1995","journal-title":"Cancer Chemother Pharmacol"},{"key":"R36-10-20210203","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1124\/dmd.105.008615","article-title":".In vitro p-glycoprotein inhibition assays for assessment of clinical drug interaction potential of new drug candidates: a recommendation for probe substrates.","volume":"34","author":"Rautio","year":"2006","journal-title":"Drug Metab Dispos"},{"key":"R37-10-20210203","first-page":"6158","article-title":"Low systemic exposure of oral docetaxel in mice resulting from extensive first-pass metabolism is boosted by ritonavir.","volume":"62","author":"Bardelmeijer","year":"2002","journal-title":"Cancer Res"},{"key":"R38-10-20210203","doi-asserted-by":"crossref","first-page":"8996","DOI":"10.1158\/0008-5472.CAN-09-2915","article-title":".Absence of both cytochrome p450 3A and p-glycoprotein dramatically increases docetaxel oral bioavailability and risk of intestinal toxicity.","volume":"69","author":"Van Waterschoot","year":"2009","journal-title":"Cancer Res"},{"key":"R39-10-20210203","first-page":"1296","article-title":"Hepatic biotransformation of docetaxel (taxotere) in vitro: involvement of the CYP3A subfamily in humans.","volume":"56","author":"Marre","year":"1996","journal-title":"Cancer Res"},{"key":"R40-10-20210203","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1097\/00008571-199810000-00004","article-title":"Role of human cytochrome p450 3A4 and 3A5 in the metabolism of taxotere and its derivatives: enzyme specificity, interindividual distribution and metabolic contribution in human liver.","volume":"8","author":"Shou","year":"1998","journal-title":"Pharmacogenetics"},{"key":"R41-10-20210203","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/0090-6980(92)90063-Y","article-title":".Synthesis and contractile activity of new pseudopeptido and thioaromatic analogues of leukotriene D4.","volume":"43","author":"Niel","year":"1992","journal-title":"Prostaglandins"},{"key":"R42-10-20210203","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1124\/mol.110.065839","article-title":"Mechanism-based inactivation of cytochrome p450 3A4 by lapatinib.","volume":"78","author":"Teng","year":"2010","journal-title":"Mol Pharmacol"},{"key":"R43-10-20210203","first-page":"365","article-title":"Differential metabolism of midazolam in mouse liver and intestine microsomes: a comparison of cytochrome p450 activity and expression.","volume":"33","author":"Perloff","year":"2003","journal-title":"Xenobiotica"},{"key":"R44-10-20210203","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1111\/j.1600-0773.1973.tb01507.x","article-title":"Interspecies variations in small intestinal and hepatic drug hydroxylation and glucuronidation.","volume":"33","author":"Hietanen","year":"1973","journal-title":"Acta Pharmacol Toxicol (Copenh)"},{"key":"R45-10-20210203","first-page":"1552","article-title":".Characterization of interintestinal and intraintestinal variations in human CYP3A-dependent metabolism.","volume":"283","author":"Paine","year":"1997","journal-title":"J Pharmacol Exp Ther"},{"key":"R46-10-20210203","doi-asserted-by":"crossref","first-page":"3583","DOI":"10.1172\/JCI33435","article-title":".Knockout of cytochrome p450 3A yields new mouse models for understanding xenobiotic metabolism.","volume":"117","author":"Van Herwaarden","year":"2007","journal-title":"J Clin Invest"},{"key":"R47-10-20210203","first-page":"219","article-title":"Pharmacokinetics and metabolism of anthracyclines.","volume":"17","author":"Robert","year":"1993","journal-title":"Cancer Surv"},{"key":"R48-10-20210203","first-page":"593","article-title":"Comparative mammalian metabolism of adriamycin and daunorubicin.","volume":"38","author":"Loveless","year":"1978","journal-title":"Cancer Res"}],"container-title":["Anti-Cancer Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/CAD.0b013e3283645e1a","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T18:02:53Z","timestamp":1786039373000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/00001813-201310000-00010"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,10]]},"references-count":42,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2013]]}},"URL":"https:\/\/doi.org\/10.1097\/cad.0b013e3283645e1a","relation":{},"ISSN":["0959-4973"],"issn-type":[{"value":"0959-4973","type":"print"}],"subject":[],"published":{"date-parts":[[2013,10]]}}}